Q: Many on your tax-loss list show estimated revenue growth > 100%; in more than a few cases, > 200%. In the case of marijuana stocks, this is puzzling, as many argue that prices will continue to weaken.
On what basis, then, should we place confidence in these numbers? Take HEXO, which you observed (last August) was priced at 4X forward sales, has since then declined by 45%, but is estimating revenue growth at 280%: what would it take to find its prospects 'interesting'?
On what basis, then, should we place confidence in these numbers? Take HEXO, which you observed (last August) was priced at 4X forward sales, has since then declined by 45%, but is estimating revenue growth at 280%: what would it take to find its prospects 'interesting'?